Last reviewed · How we verify

NCT03711019: CORRECT-C

Efficacy of Convulsive Therapies During Continuation

Completed NA Last updated 4 November 2024
What this trial tests

NA trial testing Magnetic Seizure Therapy (MST) in Depression in 106 participants. Completed in 10 October 2024.

Timeline
22 October 2018
Primary endpoint
10 October 2024
10 October 2024

Quick facts

Lead sponsorCentre for Addiction and Mental Health
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment106
Start date22 October 2018
Primary completion10 October 2024
Estimated completion10 October 2024
Sites3 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Centre for Addiction and Mental Health — full company profile →

Who can join

18 and older, any sex, with Depression or Bipolar Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) and two different forms of electroconvulsive therapy (ECT) in sustaining response during and after a course of continuation treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Magnetic Seizure Therapy (MST)

Trials testing the same drug.

Other recruiting trials for Depression

Currently open trials in the same condition.

Other Centre for Addiction and Mental Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03711019.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing